Anavex Life Sciences Corp. (AVXL)
NasdaqGS
Price as at 30 Sept 2026, 16:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Anavex Life Sciences Corp. trades at $2.19. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Two Sigma, TWO SIGMA INVESTMENTS, LP$7.89M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$2.49M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$2.30M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$852.4K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$407.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in AVXL
Trades in AVXL disclosed by members of Congress and executive-branch officials, latest first:
- Christopher L. Jacobs · HouseSell · $1,001 - $15,000 · traded 12 Dec 2022 · disclosed 20 Jan 2023
- Christopher L. Jacobs · HouseBuy · $1,001 - $15,000 · traded 12 Oct 2022 · disclosed 16 Nov 2022
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own AVXL?
8 of the institutions we track reported a position in AVXL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its AVXL data?
Fundamentals for AVXL come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:16 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AVXL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.